TY - JOUR
T1 - A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
AU - Borthakur, Gautam
AU - Dombret, Herve
AU - Schafhausen, Philippe
AU - Brummendorf, Tim Henrik
AU - Boisse, Nicolas
AU - Jabbour, Elias
AU - Mariani, Mariangela
AU - Capolongo, Laura
AU - Carpinelli, Patrizia
AU - Davite, Cristina
AU - Kantarjian, Hagop
AU - Cortes, Jorge E.
N1 - Publisher Copyright:
© 2015 Ferrata Storti Foundation.
PY - 2015/7/6
Y1 - 2015/7/6
N2 - Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Two dosing schedules were studied: schedule A, in which danusertib was given by 3-hour intravenous infusion daily for 7 consecutive days (days 1-7) in a 14-day cycle, and schedule B, in which the danusertib was given by 3-hour intravenous infusion daily for 14 consecutive days (days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 with schedule A and eight with schedule B. The recommended phase 2 dose for schedule A was 180 mg/m2. Enrollment to schedule B was stopped early because of logistical problems with the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in schedule A. Four patients with T315I ABL kinase mutation, all treated with schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. This study was registered with the European Clinical Trails Data Base (EudraCT number 2007-004070-18).
AB - Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Two dosing schedules were studied: schedule A, in which danusertib was given by 3-hour intravenous infusion daily for 7 consecutive days (days 1-7) in a 14-day cycle, and schedule B, in which the danusertib was given by 3-hour intravenous infusion daily for 14 consecutive days (days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 with schedule A and eight with schedule B. The recommended phase 2 dose for schedule A was 180 mg/m2. Enrollment to schedule B was stopped early because of logistical problems with the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in schedule A. Four patients with T315I ABL kinase mutation, all treated with schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. This study was registered with the European Clinical Trails Data Base (EudraCT number 2007-004070-18).
UR - http://www.scopus.com/inward/record.url?scp=84936127226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936127226&partnerID=8YFLogxK
U2 - 10.3324/haematol.2014.115279
DO - 10.3324/haematol.2014.115279
M3 - Article
C2 - 25887498
AN - SCOPUS:84936127226
SN - 0390-6078
VL - 100
SP - 898
EP - 904
JO - Haematologica
JF - Haematologica
IS - 7
ER -